

# Cynthia L Gay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4129108/publications.pdf>

Version: 2024-02-01

64  
papers

3,353  
citations

186265

28  
h-index

149698

56  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac031.	0.9	4
2	Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e234-e236.	2.1	13
3	Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic. <i>Healthcare</i> , 2021, 9, 100581.	1.3	1
4	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 92-100.	4.0	57
5	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	12.6	145
6	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020, 34, 1923-1931.	2.2	4
7	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1843-1852.	4.0	22
8	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020, 10, 5134.	3.3	32
9	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	28.9	126
10	Phylogenetic Analysis Complements Partner Services by Identifying Acute and Unreported HIV Transmission. <i>Viruses</i> , 2020, 12, 145.	3.3	15
11	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020, 9, .	6.0	25
12	Results of a Social Network Testing Intervention for HIV in Infectious Disease Clinics. <i>AIDS and Behavior</i> , 2019, 23, 48-51.	2.7	5
13	Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	38
14	HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 9-17.	4.1	19
15	Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 821-830.	4.7	13
16	Performance evaluation of the Bio-Rad Geenius HIV 1/2 supplemental assay. <i>Journal of Clinical Virology</i> , 2019, 111, 24-28.	3.1	10
17	Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 111-122.	1.1	48
18	Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. <i>Antiviral Therapy</i> , 2018, 24, 45-50.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 510-518.	2.1	29
20	HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018, 26, 2496-2506.	8.2	32
21	Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. <i>Antiviral Therapy</i> , 2018, 23, 495-504.	1.0	6
22	T cells establish and maintain CNS viral infection in HIV-infected humanized mice. <i>Journal of Clinical Investigation</i> , 2018, 128, 2862-2876.	8.2	41
23	Diagnosing acute HIV infection: The performance of quantitative HIV-1 RNA testing (viral load) in the 2014 laboratory testing algorithm. <i>Journal of Clinical Virology</i> , 2017, 93, 85-86.	3.1	3
24	HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 513-523.	1.1	27
25	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1725-1733.	4.0	196
26	Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1731-1740.	3.0	50
27	Performance evaluation of the FDA-approved Determine <sup>®</sup> HIV-1/2 Ag/Ab Combo assay using plasma and whole blood specimens. <i>Journal of Clinical Virology</i> , 2017, 91, 95-100.	3.1	22
28	Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. <i>EBioMedicine</i> , 2017, 23, 52-58.	6.1	29
29	Integrating a Statewide HIV Call Line: An Innovative and Tailored Approach for Rapid Linkage to HIV Care. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 953-963.	1.0	1
30	Sexual and reproductive health outcomes among female sex workers in Johannesburg and Pretoria, South Africa: Recommendations for public health programmes. <i>BMC Public Health</i> , 2017, 17, 442.	2.9	22
31	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017, 127, 3126-3135.	8.2	165
32	Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 111-119.	2.1	21
33	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. <i>Aids</i> , 2016, 30, 2815-2822.	2.2	4
34	Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 682.	7.4	46
35	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4077-4090.	8.2	124
36	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015, 212, 1361-1365.	4.0	362

#	ARTICLE	IF	CITATIONS
37	Detecting HIV Among Persons Accompanying Patients to an Infectious Diseases Clinic. Sexually Transmitted Diseases, 2015, 42, 54-56.	1.7	4
38	Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. PLoS ONE, 2015, 10, e0127950.	2.5	26
39	Unreported Male Sex Partners Among Men with Newly Diagnosed HIV Infection " North Carolina, 2011"2013. Morbidity and Mortality Weekly Report, 2015, 64, 1037-1041.	15.1	3
40	Surveillance of HIV in the United States and England, Wales, and Northern Ireland. Sexually Transmitted Diseases, 2014, 41, 266-267.	1.7	0
41	Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior After Diagnosis of Acute HIV. Sexually Transmitted Diseases, 2014, 41, 447-452.	1.7	13
42	Implementation of a Collaborative HIV Testing Model Between an Emergency Department and Infectious Disease Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, e67-e70.	2.1	2
43	"No One"™s at Home and They Won"™t Pick up the Phone" Sexually Transmitted Diseases, 2014, 41, 143-148.	1.7	36
44	Missed Opportunities for Concurrent HIV-STD Testing in an Academic Emergency Department. Public Health Reports, 2014, 129, 12-20.	2.5	22
45	Acute HIV-1 Infection in the Southeastern United States: A Cohort Study. AIDS Research and Human Retroviruses, 2013, 29, 121-128.	1.1	33
46	Patient Retention From HIV Diagnosis Through One Year on Antiretroviral Therapy at a Primary Health Care Clinic in Johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e39-e46.	2.1	87
47	Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 505-508.	2.1	49
48	Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. Aids, 2013, 27, 645-650.	2.2	51
49	CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection. Journal of Immunology, 2012, 188, 4289-4296.	0.8	63
50	Immediate antiviral therapy appears to restrict resting CD4 <sup>+</sup> cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9523-9528.	7.1	202
51	Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. PLoS ONE, 2011, 6, e19617.	2.5	65
52	Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. Aids, 2011, 25, 941-949.	2.2	25
53	Prospective study of the ARCHITECTHIV Ag/Ab Combo fourth generation assay to detect HIV infection in sexually transmitted infection clinics. Aids, 2011, 25, 1927-1929.	2.2	7
54	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	4.7	90

#	ARTICLE	IF	CITATIONS
55	The Gap between Human Immunodeficiency Virus (HIV) Infection and Advances in HIV Treatment. <i>Clinical Infectious Diseases</i> , 2010, 50, 1521-1523.	5.8	0
56	The Detection of Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, S270-S277.	4.0	230
57	Treatment to Prevent Transmission of HIV. <i>Clinical Infectious Diseases</i> , 2010, 50, S85-S95.	5.8	164
58	Acute HIV infection among pregnant women in Malawi. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 356-360.	1.8	13
59	Using antiretrovirals to prevent HIV transmission. , 2009, , 107-145.		2
60	Antiretrovirals to prevent HIV infection: Pre-and postexposure prophylaxis. <i>Current Infectious Disease Reports</i> , 2008, 10, 323-331.	3.0	19
61	Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1. <i>Annals of Internal Medicine</i> , 2007, 146, 591.	3.9	202
62	Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. <i>Aids</i> , 2006, 20, 775-778.	2.2	36
63	HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note. <i>Clinical Infectious Diseases</i> , 2005, 41, 1514-1516.	5.8	2
64	Acute HIV revisited: new opportunities for treatment and prevention. <i>Journal of Clinical Investigation</i> , 2004, 113, 937-945.	8.2	130